IP Law Daily
A complete daily report of the intellectual property news that affects your practice, your clients and your world.
Breaking news and expert analysis on Intellectual Property Law.
What good is the right knowledge if it’s at the wrong time?
A complete daily report of the news that affects your world
- View full summaries of federal and state court decisions
- Access full text of legislative and regulatory developments
- Customize your daily email by topic and/or jurisdiction
- Search archives for stories of interest
Not just news – the right news
- Get expert analysis written by subject matter specialists—created by attorneys for attorneys
- Track law firms and organizations in the headlines with our new “Who’s in the News” feature
- Promote your firm with our permissions policy.
24/7 access for a 24/7 world
- Forward information with special copyright permissions, encouraging collaboration between counsel and colleagues
- Save time with mobile apps for your iPhone, iPad, or Android
- Access all links from any mobile device without being prompted for user name and password
Logical relationship-type test applies when evaluating whether amended patent infringement claims relate back to original complaint
Claims asserted by Anza Technologies in a second amended complaint against Mushkin, Inc., were not time-barred because they related back to the complaint originally filed in another district.
Weight loss drug patent claims invalid as obvious
Although the patents covering Contrave® contained an adequate written description, the weight loss properties of the drug were well known to the industry prior to the issuance of the patent.
Misappropriation and correction of inventorship claims in sensor patent dispute properly dismissed
Federal Circuit affirms that trade secret claims cannot be backdated to subsequent discoveries of misappropriation.
Patent infringement claims brought by gaming machine developer transferred
Under TC Heartland, New Jersey was not a proper venue for patent claims asserted by High 5 Games.
Court affirms validity of Amgen’s patents for rheumatoid arthritis drug Enbrel
The court concluded the patent claims are not invalid based on challenges for lack of written description and obviousness.